Cleared Traditional

K070217 - INTERX 1000/DERMA 200 STIMULATOR FOR COSMETIC USE

K070217 is an FDA 510(k) clearance for INTERX 1000/DERMA 200 STIMULATOR FOR CO..., manufactured by Neuro Resource Group, Inc.. The device is a Class 2 Neurology device with product code NFO cleared through the Traditional 510(k) pathway after a 437-day FDA review.

K070217 · Neuro Resource Group, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2008
Decision
437d
Days
Class 2
Risk

K070217 is an FDA 510(k) clearance for the INTERX 1000/DERMA 200 STIMULATOR FOR COSMETIC USE. Classified as Stimulator, Transcutaneous Electrical, Aesthetic Purposes (product code NFO), Class II - Special Controls.

Submitted by Neuro Resource Group, Inc. (Plano, US). The FDA issued a Cleared decision on April 4, 2008 after a review of 437 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5890 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Neurology submissions.

View all Neuro Resource Group, Inc. devices

FDA 510(k) Submission Details - K070217

510(k) Number K070217 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 23, 2007
Decision Date April 04, 2008
Days to Decision 437 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
289d slower than avg
Panel avg: 148d · This submission: 437d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NFO Device Classification - Class 2, Special Controls

Product Code NFO Stimulator, Transcutaneous Electrical, Aesthetic Purposes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5890
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.